Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New texting system aims to boost cervical cancer screening in kenya

NCT ID NCT06286462

Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a web-based tool called the Cancer Tracking System (CATSystem) that sends automated texts and alerts to help women in Kenya get timely cervical cancer screening and follow-up care. About 6,600 women across 10 hospitals will take part, with half the hospitals using the system and half providing standard care. The goal is to see if the system increases the number of women who receive guideline-recommended treatment after a positive screen.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cancer Tracking System (CATSystem) - a web-based tool that sends reminders and tracks patient care
What this could lead to
If successful, this system could help more women get timely screening and treatment for cervical cancer, reducing preventable deaths in Kenya.
What could go wrong
This is a relatively early-stage implementation study, and the system's effectiveness may vary across different hospital settings. It also relies on cell phone access, which may not be universal.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 6,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2024

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * women above 16 years of age * access to a cell phone, * presenting for cervical cancer screening at a study hospital. Exclusion Criteria: * greater than 20 weeks gestation, * incarcerated patients, * women who study staff feel are unable to provide written informed consent due to impaired capacity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

Contacts and locations

Locations

  • Akala Health Center

    Akala, Kenya

  • Alupe Sub-County Hospital

    Busia, Kenya

  • Bondo Referral Hospital

    Bondo, Kenya

  • Busia County Referral Hospital

    Busia, Kenya

  • Khunyangu Sub-County Hospital

    Busia, Kenya

  • Matayos Health Center

    Busia, Kenya

  • Nambale Sub-County Hospital

    Siaya, Kenya

  • Port Victoria Sub-County Hospital

    Busia, Kenya

  • Ukwala Sub-County Hospital

    Ukwala, Kenya

  • Yala Sub-County Hospital

    Siaya, Kenya

More trials for these conditions

Other studies related to the condition(s) this trial covers.